Increased BRCA1 protein in mammary tumours of rats fed marine ω-3 fatty acids

Jourdan, Marie-Lise; Mahéo, Karine; Barascu, Aurélia; Goupille, Caroline; Latour, Monique Peffault De; Bougnoux, Philippe; Rio, Pascale

doi:10.3892/or.17.4.713

Cited by 24 publications

(28 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These include dietary supplementation of mouse transplantable tumors (71) and human cell xenograft models (72,73) as well as chemically induced tumors in rats (74,75,76). A recent report showed that dietary DHA-induced reduction in mammary tumors in a rat model was accompanied by a 60% increase in BRCA1 tumor suppressor protein (77). Interestingly, n-3 fatty acid-enriched diets enhanced the efficiency of doxorubicin (78) and mitomycin C (79) in inhibiting tumor growth and strengthened the inhibitory effect of tamoxifen in estrogendependent xenografts (80).…”

Section: Models Of Breast Cancermentioning

confidence: 99%

Multi-targeted therapy of cancer by omega-3 fatty acids

2008

View full text Add to dashboard Cite

Omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) are essential fatty acids necessary for human health. Currently, the Western diet contains a disproportionally high amount of n-6 PUFAs and low amount of n-3 PUFAs, and the resulting high n-6/n-3 ratio is thought to contribute to cardiovascular disease, inflammation, and cancer. Studies in human populations have linked high consumption of fish or fish oil to reduced risk of colon, prostate and breast cancer, although other studies failed to find a significant association. Nonetheless, the available epidemiological evidence, combined with the demonstrated effects of n-3 PUFAs on cancer in animal and cell culture models, has motivated the development of clinical interventions using n-3 PUFAs in the prevention and treatment of cancer, as well as for nutritional support of cancer patients to reduce weight loss and modulate the immune system. In this review, we discuss the rationale for using long-chain n-3 PUFAs in cancer prevention and treatment and the challenges that such approaches pose in the design of clinical trials.

show abstract

Section: Models Of Breast Cancermentioning

confidence: 99%

Multi-targeted therapy of cancer by omega-3 fatty acids

2008

View full text Add to dashboard Cite

show abstract

“…A review of 81 rodent studies concluded that dietary omega-6 fatty acids dose-dependently accelerate mammary tumorigenesis (11). Conversely, dietary EPA and DHA prevent mammary tumor development in animals (12)(13)(14)(15). The effect of omega-3 and omega-6 intake on breast cancer risk in humans has not been determined.…”

Section: Introductionmentioning

confidence: 99%

Omega-3 and Omega-6 Fatty Acids in Blood and Breast Tissue of High-Risk Women and Association with Atypical Cytomorphology

Hidaka

Harvey

et al. 2015

Cancer Prevention Research

View full text Add to dashboard Cite

The ratio of omega-3 to omega-6 fatty acids, especially the longchain eicosapentaenoic acid (EPA) þ docosahexaenoic acid (DHA) to arachidonic acid (AA) ratio, is inversely associated with breast cancer risk. We measured the association between cytologic atypia, a biomarker for short-term risk of breast cancer development, and omega-3 and omega-6 fatty acid intake and levels in blood and breast tissue. Blood and benign breast tissue, sampled by random periareolar fine-needle aspiration (RPFNA), was obtained from 70 women at elevated risk for breast cancer. Self-reported dietary intake was assessed by the NCI's Food Frequency Questionnaire. The fatty acid composition of five lipid compartments, red blood cell, plasma and breast phospholipids, and plasma and breast triaclyglycerides (TAG), was analyzed by gas chromatography as weight percent. Median daily intakes of EPAþDHA and total omega-3 fatty acids were 80 mg and 1.1 g, respectively. The median total omega-3:6 intake ratio was 1:10. Compared with women without atypia, those with cytologic atypia had lower total omega-3 fatty acids in red blood cell and plasma phospholipids and lower omega-3:6 ratios in plasma TAGs and breast TAGs (P < 0.05). The EPAþDHA:AA ratio in plasma TAGs was also lower among women with atypia. This is the first report of associations between tissue levels of omega-3 and omega-6 fatty acids and a reversible tissue biomarker of breast cancer risk. RPFNA cytomorphology could serve as a surrogate endpoint for breast cancer prevention trials of omega-3 fatty acid supplementation. Cancer Prev Res; 8(5); 359-64. Ó2015 AACR.

show abstract

“…(54) Interestingly, n-3 fatty acidenriched diets enhanced the efficiency of doxorubicin (55) and mitomycin C (56) in inhibiting tumor growth and strengthened the inhibitory effect of tamoxifen in estrogen dependent xenografts.These studies point to a potential value of n-3 fatty acids as adjuvant to standard chemotherapy. (58) There are many molecular mechanisms by which omega-3 PUFA may exerts their potential effects on the cancer cells.…”

Section: Discussionmentioning

confidence: 99%

“…PPAR-γ negatively regulates several genes, including NF-κB gene. The ability of PPAR-γ to inhibit NF-κ B expression is important in breast cancer progression (5,6).…”

Section: Introductionmentioning

confidence: 99%

Peroxisome Proliferator- Activated Receptor-gamma and Nuclear Factor-kappa B in Obese Breast Cancer Patients: Correlation with Omega-3 polyunsaturated Fatty Acids with Adjuvant Chemotherapy

Sharaf¹,

Kamel²,

El-Tahan³

et al. 2017

Int. J. Adv. Res. Biol. Sci.

View full text Add to dashboard Cite

Background: PPAR-γ has been reported to affect cell proliferation/differentiation pathways in various malignancies. PPAR-γ negatively regulates NF-κB gene which is important in breast cancer progression. Objective: The present study was designed to evaluate the relationship between PPAR-γ and NF-κB and the clinicopathological parameters of breast cancer women. The possible effects of adjuvant omega-3 fatty acid treatment with chemotherapy was also studied. Methods: 40 obese breast cancer patients was subdivided into two groups(20 each),chemo group received chemotherapy alone and omega group received 2 gm n-3 daily wih chemotherapy and control group included 20 obese women. Serum PPAR-γ and NF-κB levels were conducted for all the studied groups. Results: PPAR-γ was significantly lower than control .The level was decreased with increased positivity of ER, PR and increased with Her-2/neu in pre-and postmenopausal breast cancer patients. NF-κB significantly higher than controls and decreased with the increased positivity of ER, PR and Her-2/neu in pre-and postmenopausal breast cancer patients. Omega-3 FAs treatment with chemotherapy significantly enhances the level of PPAR-γ and decreases NF-κB level. Conclusion:The using of omega-3 PUFA as adjuvant treatment may increase sensitivity of cancer cells for chemotherapy by targeting PPAR-γ /NF-κB signaling pathway through correction of their derangements.

show abstract

Increased BRCA1 protein in mammary tumours of rats fed marine ω-3 fatty acids

Cited by 24 publications

References 47 publications

Multi-targeted therapy of cancer by omega-3 fatty acids

Multi-targeted therapy of cancer by omega-3 fatty acids

Omega-3 and Omega-6 Fatty Acids in Blood and Breast Tissue of High-Risk Women and Association with Atypical Cytomorphology

Peroxisome Proliferator- Activated Receptor-gamma and Nuclear Factor-kappa B in Obese Breast Cancer Patients: Correlation with Omega-3 polyunsaturated Fatty Acids with Adjuvant Chemotherapy

Contact Info

Product

Resources

About